Stone RM, O'Donnell MR, Sekeres MA. - Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program, 2004, 98-117.
Zittoun RA, Mandelli F, Willemze R, et al. - Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med, 1995, 332, 217-223.
Suciu S, Mandelli F, de Witte T, et al. - Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1) : an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood, 2003, 102, 1232-1240.
Weiden PL, Flournoy N, Thomas ED, et al. - Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med, 1979, 300, 1068-1073.
Jehn U, Suciu S, Thomas X, et al. - Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial. Leukemia, 2006, 20, 1723-1730.
Appelbaum FR, Gundacker H, Head DR, et al. - Age and acute myeloid leukemia. Blood, 2006, 107, 3481-3485.
Baron F, Storb R. - Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders (Review). Molecular Therapy, 2006, 13, 26-41.
Baron F, Maris MB, Sandmaier BM, et al. - Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol, 2005, 23, 1993-2003.
Tauro S, Craddock C, Peggs K, et al. - Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol, 2005, 23, 9387-9393.
Hegenbart U, Niederwieser D, Sandmaier BM, et al. - Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol, 2006, 24, 444-453.
Blaise DP, Michel BJ, Faucher C, et al. - Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer, 2005, 104, 1931-1938.
Baron F, Storb R. - Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Curr Opin Hematol, 2007, 14, 145-151.
de Lima M, Giralt S. - Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. Semin Hematol, 2006, 43, 107-117.
Aoudjhane M, Labopin M, Gorin NC, et al. - Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia, 2005, 19, 2304-2312.,
Scott BL, Sandmaier BM, Storer B, et al. - Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia, 2006, 20, 128-135.
Sorror ML, Maris MB, Storb R, et al. - Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 2005, 106, 2912-2919.
Sorror ML, Sandmaier BM, Storer BE, et al. - Comorbidity and Disease Status Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation. J Clin Oncol, 2007, 25, 4246-4254.
Amadori S, Suciu S, Jehn U, et al. - Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood, 2005, 106, 27-34.
Stone RM, DeAngelo DJ, Klimek V, et al. - Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood, 2005, 105, 54-60.
Knapper S, Burnett AK, Littlewood T, et al. - A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood, 2006, 108, 3262-3270.
Lancet JE, Gojo I, Gotlib J, et al. - A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood, 2007, 109, 1387-1394.
Larson RA, Boogaerts M, Estey E, et al. - Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia, 2002, 16, 1627-1636.